Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Trial details
- Registry ID
- NCT00625586
- Phase
- Phase 2
The FDA approved Gemcitabine (Gemzar) on 15 May 1996.
Drug identity checked against registry records
Also recorded as Gemzar; gemcitabine hydrocholoride
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1996-05-15Day | Gemcitabine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020509", "applicant_as_listed_by_fda": "LILLY", "brand_names": ["GEMZAR"], "active_ingredients": ["GEMCITABINE HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960515", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |